Drugs / TH-SC01
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06925607 | Apr 2025 → Mar 2026 overdue | radiation proctitis | Jiangsu Topcel-KH Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06429241 | Apr → Nov 2024 | Crohn disease, anal fistula | Jiangsu Topcel-KH Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05939778 | Sep 2022 → Jan 2024 | rectal disorder | Jinling Hospital, China | Unknown | No outcome recorded |
| Phase 1 | NCT04939337 | Nov 2020 → Jan 2024 | perianal Crohn disease | Jinling Hospital, China | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05677672 | Dec 2022 → Aug 2023 | anal fistula | Jiangsu Topcel-KH Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05626023 | Jan 2022 → Aug 2023 | Crohn disease, anal fistula | Jiangsu Topcel-KH Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TH-SC01 | “Evaluate the Distribution and Dynamic Behavior of Nuclide Labeled TH-SC01 Cells in Vivo in Patients With Radiation Proctitis” NCT06925607 ↗ |
| Known as | Human TH-SC01 Cell Injection | “Human TH-SC01 Cell Injection is a human expanded umbilical cord mesenchymal stem cells suspension” NCT05677672 ↗ |
| Modality | Cell therapy | “Allogeneic Umbilical Cord-derived Mesenchymal Stem cells perilesional injection.” NCT04939337 ↗ |
| Route | Other | “Endoscopic Local Injection” NCT05939778 ↗ |